These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804 [TBL] [Abstract][Full Text] [Related]
10. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440 [TBL] [Abstract][Full Text] [Related]
11. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate. Sesanto R; Kuehn JF; Barber DL; White KA Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606 [TBL] [Abstract][Full Text] [Related]
12. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394 [TBL] [Abstract][Full Text] [Related]
13. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596 [TBL] [Abstract][Full Text] [Related]
14. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816 [TBL] [Abstract][Full Text] [Related]
16. Peeters TH; Lenting K; Breukels V; van Lith SAM; van den Heuvel CNAM; Molenaar R; van Rooij A; Wevers R; Span PN; Heerschap A; Leenders WPJ Cancer Metab; 2019; 7():4. PubMed ID: 31139406 [TBL] [Abstract][Full Text] [Related]
17. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206 [TBL] [Abstract][Full Text] [Related]
18. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659 [TBL] [Abstract][Full Text] [Related]
19. Heterozygous IDH1 Wei S; Wang J; Oyinlade O; Ma D; Wang S; Kratz L; Lal B; Xu Q; Liu S; Shah SR; Zhang H; Li Y; Quiñones-Hinojosa A; Zhu H; Huang ZY; Cheng L; Qian J; Xia S Oncogene; 2018 Sep; 37(38):5160-5174. PubMed ID: 29849122 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]